Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: autologous dendritic cell cancer vaccine Clear all
Completed Phase 2 Interventional Results available

Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139

NCT02362464
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasms of Prostate, Prostate Cancer, Cancer Of Prostate, Stage D0 Prostate Cancer
Interventions
Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

NCT01339663
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
cyclophosphamide, aldesleukin, autologous tumor cell vaccine, laboratory biomarker analysis, immunologic technique, immunohistochemistry staining method, polymerase chain reaction, therapeutic autologous lymphocytes
Drug · Biological · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

NCT00683241
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer
Interventions
DCVac-L
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

NCT02678741
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
TLPLDC Vaccine
Drug
Lead sponsor
Elios Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00085488
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
autologous tumor cell vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 9, 2026, 1:41 PM EDT
Recruiting Phase 2 Interventional

Autologous Dendritic Cell Vaccine in Kidney Cancer

NCT05127824
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Autologous alpha-DC1/TBVA vaccine, Cabozantinib
Biological · Drug
Lead sponsor
Jodi Maranchie
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

NCT01635283
View directory record Official record
Conditions
Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Tumor, Adult Oligoastrocytoma
Interventions
tumor lysate-pulsed autologous dendritic cell vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 9, 2026, 1:41 PM EDT
Terminated Phase 2 Interventional Results available

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

NCT01353222
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
DN24-02, Standard of Care
Biological · Other
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
60
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01239875
View directory record Official record
Conditions
Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Adult Diffuse Mixed Cell Lymphoma, Adult Diffuse Small Cleaved Cell Lymphoma, Adult Grade III Lymphomatoid Granulomatosis, Adult Immunoblastic Large Cell Lymphoma, Adult Lymphoblastic Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3 Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia With Nodal Disease
Interventions
dendritic cell vaccine therapy, cryotherapy, pneumococcal polyvalent vaccine, laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, autologous dendritic cell-tumor fusion vaccine
Biological · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

NCT00490529
View directory record Official record
Conditions
Lymphoma, Mantle-Cell
Interventions
CpG-MCL vaccine, PF-3512676, Vaccine-primed T-cells, Autologous hematopoietic stem cell transplant (HSCT), Rituximab, Standard induction chemotherapy, Cyclophosphamide, Filgrastim
Biological · Procedure · Drug
Lead sponsor
Ronald Levy
Other
Eligibility
21 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)

NCT01671592
View directory record Official record
Conditions
Colorectal Neoplasms, Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions
DC Vaccine
Biological
Lead sponsor
Pawel Kalinski
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells

NCT00672542
View directory record Official record
Conditions
Metastatic Melanoma, Absence of CNS Metastases
Interventions
Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
Biological
Lead sponsor
Scott Pruitt
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Oct 9, 2026, 1:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

NCT06253494
View directory record Official record
Conditions
Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
Interventions
AdHER2DC vaccine, Pembrolizumab, N-803, Lenvatinib, PATHWAY HER2 (4B5) assay
Biological · Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 9, 2026, 1:41 PM EDT
Terminated Phase 1 Interventional

Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor

NCT00377247
View directory record Official record
Conditions
Primary Advanced Carcinoma of the Oral Cavity or Oropharynx, Squamous Cell Carcinoma of the Head and Neck
Interventions
autologous monocyte-derived dendritic cells (DC) transfected with DNA
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
37 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

NCT00019084
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, sargramostim, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Phase IIB TL + YCWP + DC in Melanoma

NCT02301611
View directory record Official record
Conditions
Melanoma
Interventions
TLPLDC, Placebo
Drug
Lead sponsor
Elios Therapeutics, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 9, 2026, 1:41 PM EDT
Not listed Phase 1 Interventional

A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer

NCT00715832
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dendritic Cell Vaccination
Biological
Lead sponsor
Southern Cancer Center
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2009 · Synced Oct 9, 2026, 1:41 PM EDT
Recruiting Phase 1 Interventional

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

NCT07374029
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Interventions
DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine, Venetoclax, GM-CSF
Biological · Drug
Lead sponsor
David Avigan
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 9, 2026, 1:41 PM EDT
Terminated Phase 2 Interventional Results available

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

NCT00704938
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, autologous dendritic cell-adenovirus p53 vaccine, filgrastim, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 9, 2026, 1:41 PM EDT
Terminated Phase 2 Interventional Results available

Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer

NCT02362451
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
Autologus elutriated monocyte placebo vaccine, Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 9, 2026, 1:41 PM EDT
Terminated Phase 2 Interventional Results available

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer

NCT01338012
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Laguna Hills, California • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer

NCT00005816
View directory record Official record
Conditions
Kidney Cancer
Interventions
therapeutic autologous dendritic cells, conventional surgery
Biological · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 9, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00612001
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 9, 2026, 1:41 PM EDT
Terminated Phase 1Phase 2 Interventional

Immunotherapy in Treating Patients With Metastatic Breast Cancer

NCT00003432
View directory record Official record
Conditions
Breast Cancer
Interventions
carcinoembryonic antigen RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 9, 2026, 1:41 PM EDT